EVAX News and Press, Evaxion Biotech A/S From 09/25/25

2025-09-25 08:04:48 ET More on Evaxion Biotech ADS, Merck Merck: Undervalued Pharma Stock With Defensive Approach And Compelling Dividend Yield Merck: Buy This Dividend Powerhouse While It's Cheap Merck & Co., Inc. (MRK) Presents At Morgan Stanley 23rd Annual Glo...

MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion’s cash runway to first half of 2027 MSD will assume full responsibility for the further development of EVX-B3 with Evaxion eligible for development, regulatory and sales mi...

Evaxion will provide scientific and company updates at numerous conferences in both the US, Europe and Asia during the coming months COPENHAGEN, Denmark, August 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing...

2025-08-14 07:59:57 ET More on Evaxion Biotech ADS Evaxion A/S 2025 Q1 - Results - Earnings Call Presentation Evaxion A/S (EVAX) Q1 2025 Earnings Call Transcript Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025 Evaxion finalizes agreement wit...

COPENHAGEN, Denmark, August 14, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces second quarter 2025 financial results. Business highlights ...

Century Therapeutics Inc. (IPSC) is expected to report $-0.38 for Q2 2025 Birchtech Corp Com (BCHT) is expected to report for Q2 2025 Cellectar Biosciences Inc. (CLRB) is expected to report $-3.6 for Q2 2025 Acuren Corporation (TIC) is expected to report for quarter end 2025-06-30 ...

COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2025 financial results on Thursday August 1...

Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, B.C. , July 29, 2025 /CNW/ -- Equity Insider News Commentary – The average ag...

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year clinical efficacy data from its phase 2 trial with lead compound EVX-01 at the...

Evaxion and the European Investment Bank (EIB) have finalized a debt settlement agreement of €3.5 million out of Evaxion’s €7 million loan with EIB, to be used for EIB to purchase €3.5 million worth of ordinary Evaxion warrants EIB will purchase the warrants at...